SYNSAM.ST
Strong BuyUnloved QualityAI neutralSynsam AB (publ) · Healthcare · Sweden · $762M
SEK 51.80 -0.4% · close 5 Oct · scored 7 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Synsam is a leading Nordic optical retailer that sells glasses on a subscription model, which gives it recurring revenue and loyal customers. It is opening new stores, running celebrity marketing campaigns and steadily repurchasing shares. It is a sound consumer business on a reasonable valuation, but analysts have cut forward earnings estimates by about 3% in the past month and there is no clear catalyst that the market is missing.
ABOUT SYNSAM AB (PUBL)
Read
Synsam AB is a leading Nordic optical retailer offering eye care services, spectacles, contact lenses, and sunglasses through a vast physical and digital store network. The company's competitive moat is anchored by its highly successful subscription-based business model, Synsam Lifestyle, which generates predictable, recurring revenue. Synsam maintains a vertically integrated supply chain, including local manufacturing in Sweden, to optimize margins and speed-to-market.
FINANCIAL SUMMARY (SEK)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.3B | 6.0B | 6.5B | 7.2B | 10.4% | 7.3B | 7.9B | 8.5B | 8.3% |
| EPS (SEK) | 2.19 | 2.08 | 2.48 | 3.14 | 12.8% | 4.01 | 4.01 | 4.65 | 21.7% |
| Shares | 149.1M | 148.4M | 146.6M | 142.8M | -4.2% | 140.7M | — | — | — |
| Debt | 3.4B | 3.3B | 3.5B | 3.6B | 1.1% | 3.7B | — | — | — |
| Equity | 2.6B | 2.5B | 2.6B | 2.4B | -1.9% | — | — | — | — |
| Op CF | 690.0M | 1.1B | 933.0M | 1.3B | 22.4% | 1.3B | — | — | — |
| Inv CF | -385.0M | -270.0M | -398.0M | -318.0M | — | — | — | — | — |
| Fin CF | -631.0M | -712.0M | -672.0M | -759.0M | — | — | — | — | — |
Calmer than 76% of stocks we rank over the past year (28% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SYNSAM.ST are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SYNSAM.ST | Synsam AB (publ)(you) | $762M | 91 | Strong Buy |
| BONEX.ST | Bonesupport Holding AB (publ) | $1.4B | 67 | Buy |
| ALIF-B.ST | AddLife AB (publ) | $2.1B | 67 | Buy |
| STIL.ST | Stille AB | $229M | 62 | Hold |
| DYVOX.ST | Dynavox Group AB (publ) | $822M | 38 | Hold |
| ARJO-B.ST | Arjo AB (publ) | $792M | 92 | Strong Buy |
| APOTEA.ST | Apotea AB (publ) | $860M | 81 | Strong Buy |
| AMBEA.ST | Ambea AB (publ) | $1.3B | 86 | Strong Buy |
| HUM.ST | Humana AB (publ) | $327M | 88 | Strong Buy |
| BIOG-B.ST | BioGaia AB (publ) | $1.1B | 77 | Buy |
Peer medians: ROE 4.1% · P/E 33.9x · Gross margin 64.1%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.